The clinical characteristics of new-onset SLE patients diagnosed with 2019 criteria
| Clinical criteria | Positive/total patients (%) |
| N | 96 |
| Fever | 40/96 (42) |
| Cutaneous domain | |
| Acute cutaneous lupus | 24/96 (25) |
| Subacute cutaneous lupus or discord rash | 25/96 (26) |
| Non-scaring alopecia | 19/96 (20) |
| Oral ulcer | 18/96 (19) |
| Arthritis domain | 51/96 (53) |
| Serositis domain | 25/96 (26) |
| Pleural or pericardial effusion | 21/96 (22) |
| Acute pericarditis | 4/96 (4) |
| Renal domain | 37/96 (39) |
| Protein >0.5 g/24 hours | 37/96 (39) |
| Class Ⅱ or Ⅴ lupus nephritis | 0/96 (0) |
| Class Ⅲ or Ⅳ lupus nephritis | 0/96 (0) |
| Neurologic domain | |
| Seizure | 0/96 (0) |
| Psychosis | 0/96 (0) |
| Delirium | 0/96 (0) |
| Haematologic domain | |
| Leucopenia | 61/96 (64) |
| Thrombocytopenia | 31/96 (32) |
| Autoimmune haemolysis | 57/96 (59) |
| Laboratory criteria | Positive/total patients (%) |
| Immunologic | |
| Anticardiolipin antibodies | 10/96 (10) |
| Antibeta2-glycoprotein antibodies | 23/96 (24) |
| Lupus anticoagulant | 26/96 (27) |
| Complement domain | 86/96 (90) |
| Highly specific antibodies domain | |
| Anti-dsDNA antibody | 87/96 (91) |
| Anti-Sm antibody | 20/96 (21) |
Anti-dsDNA, antibodies to double-stranded DNA; Anti-Sm, anti-Smith; SLE, systemic lupus erythematosus.